Running title: CD24 induces drug resistance in endometrial cancer. 
Introduction
Endometrial cancer is the most prevalent gynecological cancer in the Western World, and is the third most common cancer in females (1) . The major symptoms of endometrial cancer include dysfunctional uterine bleeding, hypermenorrhea, irregular menstruation and sterility.
Endometrial cancer is a malignant epithelial tumor, which comprises endometrioid adenocarcinomas in approximately 80% of the newly diagnosed cases in the Western world (2, 3) . These tumors resemble the normal endometrium morphologically, and are frequently preceded by endometrial hyperplasia. The current treatment for endometrial cancer involves surgery, radiotherapy and chemotherapy in combination, and this approach has improved the prognosis for patients. However, the number of patients with advanced cancers is increasing with the absolute increase in patients, and advanced cancers recur and metastasize to other organs beyond the pelvic cavity. Surgery is not applicable in these patients, so radiotherapy or/and chemotherapy is administered, but the efficacy of these treatments is limited in advanced cases, and the prognosis is poor, indicating the need for a new type of therapy (4) . The three major multidrug resistance ABC proteins are MDR1 (P-glycoprotein, ABCB1), multidrug resistance associated protein 1 (MRP1, ABCC1) and BCRP (ABCG2, placenta-specific ABC transporter). MDR1 and MRP1 can transport a variety of hydrophobic drugs, and MRP1 can also extrude anionic drugs or drug conjugates. The transport properties of BCRP overlap with those of both MDR1 and the MRP-type proteins. Thus, these three proteins form a special network involved in chemo-defense mechanisms. (12) CD24 is a highly glycosylated protein that is linked to the membrane via a glycosyl-phosphatidyl-inositol (GPI) anchor. The mature protein is only 27-30 amino acids long, and most of the molecular weight of the protein is due to the extensive N-and O-linked and neutrophils, in neuronal tissue and in certain epithelial cells, such as keratinocytes and the renal tubular epithelium. Various studies have identified CD24 as a marker for a poor prognosis in several tumors, including carcinomas of the ovary (13) , breast (14) and pancreas (15) , as well as non-small cell lung cancer (16) , colorectal cancer (17) and diffuse-type gastric adenocarcinoma (18) . In addition, high expressions of CD24 have also been reported to be associated with the poorer prognosis in endometrial cancer patients (19, 20) . An expanding body of literature points to a role for CD24 in the initiation and progression of numerous types of cancer. Some investigators have suggested that CD24 interacts with the src kinases due to its localization in detergent-resistant membrane domains (DRM; lipid rafts), (21, 22). In fact, Zarn et al. showed the association of CD24 and src kinase families in a small cell lung cancer cell line, and Sammar et al. demonstrated that CD24 and src kinases are involved in the activation of cell aggregation in a lymphoma cell line. However, the cellular mechanism(s) involved in the activity of CD24 remain largely unclear.
In the present study, we evaluated this mechanism, and how CD24 it contributes to drug resistance in endometrial cancer (EC) cell lines. 
Materials and Methods

Materials
The rabbit polyclonal anti-human MDR1 antibody, rabbit polyclonal anti-human MRP1 antibody and mouse monoclonal anti-human caveolin-1 antibody used for immunoblotting were purchased from Abcam (Cambridge, MA, USA). The rabbit polyclonal anti-human CD24 antibody used for immunoblotting and rabbit monoclonal anti-human Met antibody used for immunoblotting and immunocytochemistry were purchased from LifeSpan BioSciences, Inc (USA). The rabbit monoclonal anti-human phospho-Met antibody, rabbit polyclonal anti-human Akt antibody, rabbit polyclonal anti-human phospho-Akt antibody, rabbit polyclonal anti-human ERK antibody, rabbit polyclonal anti-human phospho-ERK antibody and rabbit monoclonal anti-human beta-actin antibody used for immunoblotting were purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA).
Cisplatin was purchased from Selleck Chemicals (Houston, TX, USA). The BD Falcon™ 96-well microplates used for the cell proliferation assays were purchased from BD Biosciences (Franklin Lakes, NJ, USA). 
Cell lines
We used two human cell lines of endometrioid adenocarcinoma. The hec-1A and hec-108 cells were obtained from the American Type Culture Collection (Rockville, MD) in 2013 and authenticated by Short Tandem Repeat (STR) polymorphism profiling analysis. Both cell lines were grown in dishes (Becton Drive, Franklin Lakes, NJ) in DMEM supplemented with 10% fetal bovine serum (Equitec-Bio, Kerrville, TX) (growth media) in an atmosphere of 5% CO 2 at 37 °C. Serum-free DMEM was used for cell starvation. The hec-1A and hec-108 cells were derived from grade 2 and grade 3 endometrioid adenocarcinoma of the uterus, respectably, and have been reported to be cisplatin resistant (23).
RNA extraction and semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA from homogenized tissue or from cultured cells was obtained using the RNeasy Mini kit (Qiagen, Germantown, MD, USA), and 2 μg were reverse-transcribed with Superscript II RNase H-reverse transcriptase (Invitrogen, Carlsbad, CA, USA) using random primers according to the manufacturer's instructions. The cDNA (1 μl) was amplified using 0. The experiments were repeated at least three times and yielded similar results.
Proliferation assay
The cells in 10% growth media were seeded in 96-well plates at a density of 2×10 Solution reagent (Promega, Tokyo, Japan) was added to each well, and the absorbance was recorded at 490 nm using a Corona SH-1000 lab absorbance microplate reader (Corona Electric Co. Inc, Ibaraki, Japan). The cell numbers were then calculated using a standard curve correlating the absorbance to the cell number counted under a microscope. All experiments were carried out in quadruplicate, and the cell viability was expressed as the ratio of the number of viable cells with cisplatin treatment to that of cells without treatment.
Western blot analysis
The cells were washed twice with ice-cold phosphate-buffered saline and lysed using The immunoreactive bands in the immunoblots were visualized with horseradish peroxidase-coupled goat anti-rabbit immunoglobulin using an enhanced chemiluminescence Western blotting system (ECL Plus, GE healthcare Life Sciences, Pittsburgh, PA, USA).
Flow cytometry
The cells were plated in six-well plates at a density of 2 × 10 5 per well and were cultured in growth media until they reached 70% to 80% confluence. 
Transfection experiments
The cell transfection with small interfering RNA (siRNA) and/or DNA construct was carried out as described in the manufacturer's protocol. Briefly, 75 pmol of siRNA or 2.5 micrograms of DNA construct per well were transiently transfected into hec-1A or hec-108 cells grown in 
CD24 isolation via magnetic beads
Hec-1A and hec-108 cells were separated into CD24-positive and CD24-negative fractions using CD24 microbeads (Miltenyi Biotec Inc.) and MACS® LD separation columns according to the manufacturer's recommendations.
Subcellular fractionation and protein precipitation
Scrambled or siRNA-CD24-treated hec-1A and hec-108 cells ( OptiprepTM (Nycomed, Amersham Biosciences) gradient, formed in 12 ml of the above buffer, and centrifuged at 4℃ for 20 h at 100,000 × g in a BECKMAN XL-100 centrifuge (Beckman, Germany). Following the centrifugation, the total volume gradient was separated into 1-ml fractions, and collected from top to bottom (from 5% to 20% OptiprepTM concentration, respectively).
The protein precipitation was as follows: the volume of each collected fraction (1 ml) was duplicated with cool acetone (1 ml, -20℃) in acetone-compatible tubes. The samples were then vortexed and incubated for 1 h at -20℃, and further centrifuged for 10 min at 13,000 × g.
Samples were decanted, and the protein pellets were resuspended in Laemmli buffer before being resolved by SDS-PAGE (12%) and Western blotting analyses using specific antibodies.
Xenogrft study
Female six-week-old athymic nude mice (BALB/c Slc-nu/nu) were used for the xenograft study.
All mice were purchased from Japan SLC, Int. and were housed three mice per cage. The mice had access to sterile food pellets and water ad libitum. The institutional guidelines for animal welfare and experimental conduct were followed. Twelve mice were injected with 10 6 hec-1A into the upper left fat pad. Two weeks after inoculation, tumor-bearing mice were randomly assigned to two groups to be treated with either vehicle (PBS) or cisplatin (3 mg/kg) once a week for two weeks. The tumor volumes were determined as described previously (24).
Animals were sacrificed three weeks after initiating treatment, and tumors were collected, snap-frozen, or fixed as described below.
Immunohistochemistry
The tumors tissue samples collected from the xenograft study were fixed in formalin and Additionally, the sections were subjected to hematoxylin and eosin staining for a histological examination with light microscopy. The slides were assessed by two experienced pathologists, and the findings were evaluated with the percentage of the sample that was stained. In cases where there was a disagreement between the examiners, the scores were reviewed together and a consensus was reached.
Statistical analyses
All experiments were performed in triplicate, except for the cell proliferation assay.
The statistical calculations were performed using the StatView statistical software package (SAS Institute, Cary, NC), and the statistical significance of each difference was determined using the Kruskal-Wallis and Mann-Whitney U test, or a paired t-test, as appropriate. A value of p < 0.05 was considered to be statistically significant. 
Results
The CD24-positive phenotype is associated with cisplatin resistance in endometrial cancer cell lines.
In order to clarify whether the CD24-positive cells are more resistant to cisplatin than their CD24-negative counterparts, the CD24 status of cisplatin-treated endometrial cell lines (EC cells) was analyzed by flow cytometry. As shown in Figure 1A , almost half of the cell population was CD24-positive in both the hec-1A and hec-108 cells. Moreover, cisplatin treatment decreased the CD24-negative cell population in both types of cells, suggesting that the CD24-positive cells are more resistant to cisplatin treatment compared to CD24-negative cells.
To confirm whether the CD24-positive cells are more resistant to cisplatin treatment than the CD24-negative cells, we divided the EC cells into CD24-positive and negative fractions using MACS, and performed a MTS assay with various concentrations of cisplatin. As shown in Figure 1B , the CD24-negative cells were more sensitive to cisplatin treatment in both cell lines.
Next, to assess whether the decrease in cell viability in the cisplatin-treated cells was the result of cell apoptosis, and to determine whether CD24 affects the apoptosis status of cells, 
an activated caspase-3 in situ detection assay was performed on vehicle (PBS)-or cisplatin-treated scrambled or CD24 siRNA-transfected EC cells. The CD24 knockdown was confirmed by using a semi-RT-PCR analysis and Western blot analysis (supplemental figure   1AB ). As shown in Figure 1C pathways are well known for increasing drug resistance (26, 27) , we assessed the PI3K/Akt and MAPK pathways using a Western blot analysis.
As shown in Figure 3A , Akt and ERK were significantly more phosphorylated in CD24-positive cells compared to CD24-negative cells. Moreover, as shown in Figure 3B , the Akt and ERK phosphorylation were significantly decreased in CD24 siRNA-transfected cells.
These data suggest that CD24 influences the PI3K/Akt and MAPK pathways.
Because the hepatocyte growth factor (HGF)/Met signaling pathway is located at upstream of both the PI3k/Akt and MAPK pathways, we anticipated that there would be a connection between CD24 and the HGF/Met signaling pathway. To determine whether CD24 has any effect on the HGF/Met signaling pathway, the Met phosphorylation status was assessed using a Western bolt analysis. As shown in Figure 3A (28), and CD24 has been reported to recruit β1 integrin to lipid raft domains (29) , or to interact with c-src within lipid rafts (30) .
To determine whether CD24 interacts with phosphorylated Met (p-Met) at lipid rafts, we performed a sucrose gradient assay and immunocytochemistry (ICC) using antibodies against p-Met or caveolin-1, a protein that acts as a scaffolding protein within caveolar membranes by compartmentalizing and concentrating signaling molecules. As shown in Figure   4A 
Discussion
In the present study, we used hec-1A and hec-108 human endometrial cancer cells to examine the relationship between CD24 and drug resistance, and revealed that CD24 was responsible for the recruitment of phosphorylated Met to the lipid raft domain of the cell membrane, resulting in amplified HGF/Met signaling and ultimately leading EC cells to express higher levels of ABC transporters.
CD24 can function as an adhesion molecule that interacts with ligands like P-selectin 
multidrug resistance by cancer cells to improve the current therapies against aggressive cancers, and to identify novel targets to prevent or circumvent resistance. It is obvious that subsequent studies will be needed, but understanding CD24-mediated drug resistance might be important for the development of new therapeutic approaches for advanced and metastatic cancers.
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